[Asia Economy Reporter Chunhee Lee] GC Green Cross announced on the 21st that the researcher-led clinical results showing that its topical hemostatic agent ‘Greenplast Q’ effectively prevents acute bleeding occurring within 48 hours after endoscopic submucosal dissection (ESD) have been published in the American Journal of Gastroenterology.
Greenplast Q is a liquid-type topical hemostatic agent derived from plasma components and is the only domestically manufactured product among distributed formulations in Korea. GC Green Cross explained, "It is available in prefilled syringe forms of 2㎖ and 4㎖, allowing easy use depending on the surgical or procedural site," adding, "The price is up to 43% cheaper compared to competing products."
ESD is a procedure that removes polyps, adenomas, and other lesions in the stomach, colon, or esophagus through endoscopy. A common side effect is subsequent bleeding. However, predicting this bleeding is difficult, and massive bleeding can be fatal to patients, so sufficient bleeding prevention during the procedure is necessary.
This study was led by Professor Sujeong Jo of the Department of Gastroenterology at Seoul National University Hospital and conducted at Seoul Asan Medical Center, Severance Hospital, and Bundang Seoul National University Hospital from October 2020 to May last year. It was a randomized controlled trial comparing bleeding occurrence after tumor resection and general hemostasis followed by Greenplast Q application versus no application in 254 high-risk patients, including those with gastric tumors larger than 40㎜ or those taking antiplatelet or anticoagulant medications prone to bleeding.
The study results showed that within 48 hours after the procedure, 5.7% of patients in the control group experienced bleeding, whereas only 0.8% of patients in the Greenplast Q-treated group experienced bleeding. It was confirmed that bleeding occurring within 48 hours post-procedure was statistically significantly reduced in high-risk patients.
Professor Sujeong Jo of Seoul National University Hospital’s Department of Gastroenterology said, “With the early detection of gastric cancer, ESD is increasing compared to open surgery, but high-risk patients taking antiplatelet and anticoagulant drugs require thorough bleeding prevention measures to avoid delayed bleeding. Although there was no difference in overall bleeding rates in this study, Greenplast Q was effective against acute bleeding within 48 hours, and considering that more than half of bleeding after ESD occurs within 48 hours, the use of Greenplast Q can be considered during high-risk procedures.”
A GC Green Cross official also stated, “About 35% of gastric cancer patients receive ESD due to the expansion of the national cancer screening program. This study is valuable as the first clinical research confirming the usefulness of active additional treatment after ESD. Since there has been a lack of active treatment options for bleeding prevention in ESD, Greenplast Q will be an effective treatment option.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
